<DOC>
	<DOCNO>NCT00005629</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness vaccine therapy treat patient liver cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria This study enroll HLAA 0201 adult age 18 history biopsyproven HCC AFP positive immunohistochemistry serum AFP level &gt; 2 time upper limit normality . Any stage disease eligible . Both male female patient may enrol . Females childbearing potential must negative pregnancy test prior treatment . Patients must ambulatory Karnofsky Performance Status great equal 70 percent . No previous evidence class 3 great New York Heart Association cardiac insufficiency coronary artery disease . No evidence opportunistic infection . A minimum 4 week must elapse since completion prior chemotherapy radiation therapy . Adequate baseline hematological function assess follow laboratory value within 30 day prior study entry ( day 30 0 ) : Hemoglobin &gt; 8.5 g/dl ( patient transfusion dependent ) . Platelets &gt; 30,000/mm3 WBC &gt; 2,000/mm3 Absolute Neutrophil Count ( ANC ) &gt; 1,000/mm3 Positive skin test common antigen ( tetanus and/or candida ) . Ability give inform consent sign informed consent . Exclusion Criteria Patients meet one follow criterion exclude study entry : Any congenital acquire condition lead inability generate immune response , include concomitant immune suppressive therapy . The ability adequately respond antigen test trial entry require positive response skin allergen ( tetanus candida ) . Lactating female : All patient must practice adequate birth control females childbearing potential must negative serum HCG pregnancy test ( within day 7 day 0 ) . Acute infection : acute viral , bacterial , fungal infection , require specific therapy . Acute therapy must complete within 14 day prior study treatment . HIVinfected patient , due concern ability stimulate effective immune response . Acute medical problem ischemic heart lung disease may consider unacceptable anesthetic operative risk . Patients underlying condition would contraindicate therapy study treatment ( allergies reagent use study ) . Patients organ allograft . Uncontrolled hepatic insufficiency cirrhosis , Class C Child 's classification , bilirubin &gt; 3 mg/dl , albumin &lt; 3.0 g/dl , poorly control ascites , advance encephalopathy poor nutritional status . Uncontrolled CNS metastasis . Patients previously know CNS metastasis eligible receive CNS irradiation control local tumor growth . Concomitant Medication Treatment : All allow medication treatment keep minimum record . Concomitant Medications Treatments Not Allowed : Corticosteroids , Cyclosporin A , cytotoxic chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>